Reviparin sodium
{{Short description|Pharmaceutical drug}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447910442
| IUPAC_name =
| image = File:Heparin General Structure V.1.svg
| tradename =
| Drugs.com = {{drugs.com|international|reviparin-sodium}}
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 9005-49-6
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 5R0L1D739E
| ATC_prefix = B01
| ATC_suffix = AB08
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB09259
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D03337
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| chemical_formula =
| molecular_weight =
}}
Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).
Medical uses
- Prevention of blood clots
- Prophylaxis of perioperative thromboembolism{{cite journal |vauthors=Kakkar VV, Cohen AT, Mohamed MS |title=Patients at risk of venous thromboembolism--clinical results with reviparin |journal=Thromb. Res. |volume=81 |issue=2 Suppl |pages=S39–45 |year=1996 |pmid=8822126 |doi=10.1016/0049-3848(95)00228-6 }}{{cite journal |vauthors=Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E |title=Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery |journal=Semin. Thromb. Hemost. |volume=25 Suppl 3 |pages=79–82 |year=1999 |pmid=10549720 }}
- Treatment of DVT with or without pulmonary embolism (PE){{cite journal |vauthors=Gore M, Kelkar P, Rege N, Ross C |title=Reviparin sodium clivarine: a review of its therapeutic use |journal=J Indian Med Assoc |volume=102 |issue=10 |pages=589–90, 592 | date=October 2004 |pmid=15887830 }}
- Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA){{cite journal |vauthors=Preisack MB, Karsch KR |title=Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty |journal=Blood Coagul. Fibrinolysis |volume=4 Suppl 1 |pages=S55–8; discussion S59–60 | date=December 1993 |pmid=8180331 }}{{cite journal |vauthors=Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R |title=Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation |journal=J. Am. Coll. Cardiol. |volume=28 |issue=6 |pages=1437–43 | date=November 1996 |pmid=8917255 |doi= 10.1016/s0735-1097(96)00343-9|hdl=1765/55740 |url=http://repub.eur.nl/pub/55740 |hdl-access=free }}
Chemistry
Reviparin is a low molecular weight heparin obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.
References
{{Reflist}}
External links
- {{MeshName|reviparin}}
- {{cite journal |vauthors=Yusuf S, Mehta SR, Xie C, etal |title=Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation |journal=JAMA |volume=293 |issue=4 |pages=427–35 |year=2005 |pmid=15671427 |doi=10.1001/jama.293.4.427|doi-access=free }}
{{Antithrombotics}}
{{blood-drug-stub}}